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Poster Session-I 83targeted therapies are thus needed to improve outcomes and immu-
notherapy has the potentials to fulfill this need. We have previously
shown that genetically modified T cells expressing a chimeric anti-
gen receptor (CAR) composed of NKG2D and the CD3-z chain
have potent antitumor activity against several adult malignancies.
Since at present only limited targets are available for the immuno-
therapy of osteosarcoma, the aim of this study was to determine if
NKG2D-ligands (NKG2D-L) are expressed on the cell surface of
osteosarcoma and if NKG2D-L-specific T cells recognize and kill
osteosarcoma.
Methods and Results:NKG2D-L expression was determined by
FACS analysis as well as RT-PCR. 7 out of 8 cell lines tested
expressed one or several NKG2D-L on their cell surface.
NKG2D-L-specific T cells were generated by transducing CD3/
CD28-activated T cells with a SFG retroviral vector encoding the
NKG2D-L-specific CAR and truncated CD19 to allow detection
of transduced T cells. NKG2D-L-specific T cells from healthy
donors produced IFN-g in contrast to mock transduced T cells after
coculture withNKG2D-L-positive osteosarcoma cells. In cytotoxic-
ity assays, NKG2D-L-specific T cells killed NKG2D-L-positive
osteosarcoma cells where as activated, autologous lymphocytes and
NKG2D-L-negatvie osteosarcoma cells were not killed.
Conclusion:We have shown that NKG2D ligands are expressed
on osteosarcoma and that NKG2D-L specific T cells recognize and
kill osteosarcoma. Murine xenograft studies are in progress to con-
firm these findings in vivo. Adoptive immunotherapy with
NKG2D-L-specific T cells may represent a promising immunother-
apeutic approach for osteosarcoma.SOLID TUMORS
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CCR2B-TRANSDUCED CYTOTOXIC T LYMPHOCYTES SHOW ENHANCED
HOMING IN VIVO TOWARD CCL2-SECRETING NEUROBLASTOMA:
IMPLICATIONS FOR ENHANCED ADOPTIVE IMMUNOTHERAPY
Craddock, J.A., Lu, A., Rooney, C.M., Foster, A.E. Baylor College of
Medicine, Houston, TX
The chemokine CCL2 (MCP-1) is produced by a variety of can-
cers including neuroblastoma, melanoma, breast cancer and hemato-
logical malignancies. However, cytotoxic T lymphocytes (CTL)
used in clinical trials to treat these diseases do not express CCR2,
the receptor for CCL2. This deficiency may contribute to subopti-
mal trafficking to tumor sites and reduced clinical efficacy. There-
fore, we examined whether genetically modifying CTL with CCR2
could increase their homing towards tumor cells that produced
CCL2. CTL were first examined by flow cytometry for chemokine
receptor expression using antibodies to CCR2, CCR4, CCR5,
CCR7 and CXCR4. These CTL showed nominal expression
of CCR2 (\1%), low expression of CCR4 (10%), CXCR4 (25%),
CCR7 (5%), and high expression of CCR5 (70%). ELISA for
CCL2 was performed on established neuroblastoma cell lines
(IMR-32, LAN-1, SK-N-SH, JF) and on neuroblastoma cell lines
derived from patients primary tumors. All neuroblastoma cell lines
secreted CCL2 in variation but notably, all patient-derived primary
tumor cell lines secreted high levels of CCL2. T cells were activated
by anti-CD3/anti-CD28 antibody stimulation for 3 days in the pres-
ence of IL-2, and then transduced using a CCR2b retroviral vector.
Expression of CCR2b was detected by flow cytometry producing up
to 78% transduction. In vitro chemotaxis of CCR2b-transduced T
cells showed enhance migration to soluble CCL2 (.3 fold) as well
as to supernatants from CCL2-secreting cell lines (.2 fold) com-
pared to non-transduced T cells. To study in vivo migration, we
co-transducedT cells with EGFPluciferase andCCR2b. Subsequent
tail vein infusion of these co-transduced T cells into mice bearing
CCL2 secreting tumors (SK-N-SH) showed preferential migration
of only CCR2b-transduced T cells toward the tumor site when com-
pared to non-transduced T cells. These results demonstrate the fea-
sibility of influencing the trafficking of adoptively transferred T cells
toward CCL2 secreting neuroblastoma and thereby suggesting a po-
tential means to enhance future adoptive immunotherapies targeting
neuroblastoma.228
HIGH DOSE CHEMOTHERAPY WITH BLOOD OR MARROW TRANSPLANT
FOR RHABDOMYOSARCOMA: A CIBMTR ANALYSIS
Stiff, P., Agovi, M.-A., Antman, K., Camitta, B., Cairo, M., Childs, R.,
Edwards, J.R., Gale, R.P., Hale, G., Horowitz, M.M., Lazarus, H.,
Arora, M. CIBMTR, Milwaukee, WI
Rhabdomyosarcoma, the commonest soft tissue sarcoma in chil-
dren is initially chemosensitive with cures in 70%, but 5 year survival
for relapsed patients is 15–20% and only 5% for those with alveolar/
undifferentiated subtypes. Since autologous stem cell transplanta-
tion (ASCT) is not clearly defined for this disease, we describe out-
comes of 62 patients who received ASCT from 1989–2003 and
reported to CIBMTR. Pathology was confirmed through review of
reports for all cases. Transplant related mortality (TRM), progres-
sion-free survival (PFS) and overall survival (OS) were evaluated.
We also compared subgroups: poor risk histology (alveolar/undiffer-
entiated, n5 34) vs good risk (embryonal/botryoid, n5 21); patients
in 1st remission (REM1, n5 38) vs patients who relapsed (REL, n5
21); those presenting with metastases (n5 39) vs those without (n5
19); patients with poor risk histology who were in REM1 (n5 20) vs
REL (n5 12) and those with good risk histology who were in REM1
(n5 13) vs REL (n5 8). For the entire cohort, 73%were\20 yrs in
age, 52% were male, 39% presented with bulk .5cm, and 63% had
metastasis at diagnosis. Fifty percent had alveolar histology, 32%
embryonal subtype, 67% were in REM1, and 92% were chemosen-
sitive at ASCT. The conditioning regimens included melphalan in
53% and etoposide in 67%. There were no differences in the remis-
sion status at ASCT (63% vs 62% in REM1; p5 0.9) or median time
from diagnosis to ASCT (p 5 0.7) for those with good vs poor risk
histology. Patients with poor risk histology were more likely to
have marrow involved at diagnosis (44 vs 14%;p5 0.2), a CR to pri-
mary therapy (53% vs 26%;p 5 0.1) and being in a CR at ASCT
(70% vs 48%;p 5 0.2). For the entire group, the TRM at 1 year
was 5% (95% CI, 1–12); the 5 year PFS and OS were 29% (95%
CI, 18–41) and 32%(95% CI, 21–44) respectively. There were no
significant difference in 5 year PFS and OS between: those with
poor risk vs good risk histology (p5 0.6;p5 0.9), those transplanted
in REM1 vs REL (36% vs 29%;p5 0.5), those with poor risk histol-
ogy transplanted in REM1 vs REL (34% vs 33%;p 5 0.9), or those
with good risk histology transplanted in REM1 vs REL (38% vs
25%;p 5 0.2). These data indicate that ASCT for this disease are
typically done for patients with chemosensitive disease and suggest
that when performed after relapse, long-term survival is seen in ap-
proximately 1/3, seemingly better than previous reports of standard
dose salvage for those with alveolar/undifferentiated histologies.229
DEPLETION OF CD4 T CELLS LEADS TO INCREASED TUMOR IMMUNITY
AFTER HSCT IMMUNOTHERAPY BUT RESULTS IN LOSS OF MEMORY
Jing, W., Johnson, B.D. Medical College of Wisconsin, Milwaukee, WI
High-risk neuroblastoma is a clinically challenging disease. We
have demonstrated that established neuroblastoma can be eliminated
in a murine model by using a multi-faceted immunotherapeutic ap-
proach involving syngeneic hematopoietic stem cell transplantation
(HSCT), T cell transfer (cellular immunotherapy), and tumor vacci-
nation. One surprising finding in these experiments was that while
depletion of CD4T cells resulted in decreased anti-tumor immunity
in mice given naı¨ve T cells as cellular immunotherapy, if the trans-
ferred T cells were pre-sensitized to tumor antigens (i.e., from
tumor-vaccinated donors) CD4 depletion resulted in increased
anti-tumor immunity. The increased anti-tumor efficacy in these
CD4-depleted hosts was accompanied by: (a) more vigorous prolif-
eration of CD8 cells in the spleens and tumor-draining lymph nodes
as observed in CFSE-labeling studies, (b) elevated percentages of
CD8T cells with a CD62L-CD441 effector phenotype, (c) elevated
frequencies and absolute numbers of splenic tumor-reactive (IFN-g-
producing) CD8 cells, and (d) more robust tumor infiltration by
CD8 cells. However, development of long-term tumor immunity
(memory) was severely compromised in these CD4-depleted hosts,
as reflected by inability to resist a tumor re-challenge and diminished
in vitro CD8 recall responses. This loss of memory occurred even
though the adoptively transferred CD8 T cells were from donors
that had been vaccinated in the presence of CD4 cells, indicating
84 Poster Session-Ithat the continued presence of CD4 T cells after HSCT is required
for the development of CD8memory. Upon investigating the mech-
anism(s) of memory loss, we observed an accelerated contraction of
tumor-reactive CD8 cells in the CD4-depleted mice. This acceler-
ated loss of tumor-reactive CD8 cells correlated with increased per-
centages of annexin-V1 pre-apoptotic CD8 cells during the
contraction phase (day 21 after HSCT). A significant proportion
of the annexin-V1 CD8 cells co-expressed programmed death re-
ceptor-1 (PD-1), had an effector phenotype (CD62L-CD441),
and expressed diminished levels of the receptors for IL-7 and IL-
15. These data suggest that PD-1/PD-L1 interactions may play
a role in the loss of CD8 memory. Together, these results show
that CD41 cells can both promote and inhibit anti-tumor responses.
These observations should help us design immunotherapeutic
approaches that can generate ‘‘optimal’’ acute anti-tumor reactivity
after HSCT with development of long-term immunity.230
LONG-TERM FOLLOW-UP OF METASTATIC RENAL CANCER PATIENTS
UNDERGOING REDUCED-INTENSITY ALLOGRAFTING
Bregni, M., Bernardi, M., Pescarollo, A., Crocchiolo, R., Treppiedi, E.,
Ciceri, F., Corradini, P., Peccatori, J. Ospedale San Giuseppe, Milano,
Italy; San Raffaele Scientific Institute, Milano, Italy; Ospedale Evangelico,
Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
Stem cell transplantation from aHLA-compatible sibling donor is
an adoptive immunotherapy for cytokine-resistant, metastatic renal
cancer (RCC). However, the recent introduction of several targeted
therapy compounds has reduced the interest in this therapeutic strat-
egy. We have reanalyzed our transplant series with the aim to detect
long-term benefit form allografting. From February 1999 to May
2005, 25 patients with cytokine-refractory RCC received a re-
duced-intensity allograft from an HLA-id sibling donor. Median
age was 53 years; most (24) had clear-cell histology. Median number
of previous treatments was 1 (0–3). Median days from diagnosis to
allograft were 822. All patients received a thiotepa, fludarabine,
and cyclophosphamide conditioning regimen, and a cyclosporine-
based GVHD prophylaxis. Six patients received DLI at escalating
doses for progressing or non-responding disease. One-year-OS
was 48% (95% CI: 28–68), and 3y-OS was 20% (95% CI: 4–36).
At a median observation time of 65 months, 5 patients are alive,
one in CR, one in VGPR, and three with stable disease.We have an-
alyzed the correlation of the following variables with survival: age at
transplant, time from diagnosis to transplant, serum calcium cor-
rected for albumin levels, lactate dehydrogenase (LDH), C-reactive
protein (CRP), haemoglobin level before transplantation, Karnofsky
performance status, number of CD341/kg infused, number of
CD31/kg infused, progressive disease at 190 after transplant, oc-
currence of acute (any grade) or chronic GvHD. At multivariate
analysis, CRP value before transplant, number of CD341 infused
cells and disease status at 190 significantly correlated with survival.
Survival of patients at favourable/intermediate-risk according to the
MSKCC score that underwent allografting was better in comparison
to the survival predicted by historical controls. We conclude that
transplantation is able to induce long-term disease control in
twenty percent of cytokine-refractory RCC patients. It is unknown
if relapse or PD after targeted therapy will be susceptible to
allograft-mediated GVT effect. The place of allografting in the
treatment of metastatic RCC, alone or in combination with targeted
therapies, needs reappraisal.231
LOW MORBIDITY AND MORTALITY IN A PILOT STUDY OF BUSULFAN,
MELPHALAN AND TOPOTECAN AS PREPARATIVE REGIMEN FOLLOWED
BY AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS WITH HIGH RISK SOLID TUMORS (PRELIMINARY
RESULTS)
Bolotin, E., Pawlowska, A., Hitt, D., Andersen, C., Shakhnovitz, M.,
Sato, J., Forman, S., Rosenthal, J. City of Hope, Duarte, CA
Autologous hematopoetic stem cell transplantation (HDT) has
been utilized as consolidative therapy for pediatric patients with
some encouraging improvement in survival. We hypothesize thatby intensifying therapy which poor prognosis patients currently
receive, it is possible to reduce the risk of relapse after HDT and
the morbidity and mortality will be acceptable. Phase I pediatric
studies of topotecan demonstrated activity against solid tumors.
The dose-limiting toxicity of Phase I studies has been hematopoietic
suppression. The use of hematopoietic stem cell support following
a topotecan-containing preparative regimen will allow utilization
of topotecan in combination with established chemotherapeutic
agents. Patients were assigned to receive topotecan at 2 mg/m2
continuous infusion in combination with fixed doses of busulfan
andmelphalan (B-M-T). In this study, the primary outcome variable
is to evaluate the toxicity of combinedHDTwith B-M-T. Secondary
objective is to analyze the engraftment and outcomes.
Results:Thirteen patients age 2–18 year old (median5 5.4) were
treated on B-M-T-protocol. Seven patients were diagnosed with
neuroblastoma (NBL),Wilms tumor (n5 2), PNET (n5 2), -rhab-
domyosarcoma (RBS) and Ewing sarcoma (each n 5 1). Eight pa-
tients were in CR, five in PR. There were no deaths in the first100
day postHDT.There was 1 admission (1day) to ICU for observation
only. Eleven patients developed grade 1–2 and 2 patients grade 3
liver toxicity (transaminitis and bilirubin elevation), all patients de-
veloped grade 2- 3 mucositis, five patients had grade 2 diarrhea,
one patient developed grade 3 respiratory toxicity, 7 patients had
metabolic toxicities grade 1–2. All patients engrafted. Patients
achieved ANC . 500 on day 8–15 (median 12), platelets .25,000
on day 9 -22 (median 16), no RBC transfusions were required after
day7–25, (median 16.2). Overall 1 1⁄2 year survival rate is 87 % (11
out of 13 patients are alive); event free survival is 78%.Three patients
had recurrent disease: 2 patients with PNET (both patients expired)
and 1 pt with NBL (alive).
Conclusions: Analysis of the preliminary data suggests that B-M-
T regimen in the context of HDT was tolerated without unexpected
or severe toxicity and allowed prompt transition to radiation and/or
maintenance therapy. Further studies are needed to document the
survival benefit of consolidation with B-M-T regimen in children
with high risk solid tumors.232
ALLOGENEIC STEM CELL IMMUNOTHERAPY FOR ADVANCED META-
STATIC BREAST CANCER: THE WAY FORWARD
Blaise, D.1, Goncalves, A.1, Furst, S.1, Bay, J.O.2, Faucher, C.1,
Michallet, M.3, Boiron, J.M.4, Cahn, J.Y.5, Gratecos, N.6, Mohty, M.7,
Chabannon, C.1, Gravis, G.1, Esterni, B.1, Extra, J.M.1, Viens, P.1 1 In-
stitut Paoli-Calmettes, Marseille, France; 2Centre Jean Perrin, Cler-
mont-Ferrand, France; 3Hopital Edouard Herriot, Lyon, France; 4EFS
Aquitaine Limousin, Bordeaux, France; 5CHU,Grenoble, France; 6Hopi-
tal Archet 1, Nice, France; 7Hotel Dieu, Nantes, France
Despite continuous advances in the treatment of mBcr, some pa-
tients have very poor outcome. Over the last period, we have inves-
tigated allogeneic immunotherapy as a possibility for tumor control
in patients with advanced mBrC. We have treated 31 pts with Allo
SCT in 2 successive clinical trials. All pts (age: 43 (27–57)) under-
went ASCT after the same RIC (Fludarabin (150mg/m2), Busulfan
(8mg/kg) and Thymoglobulin (2,5mg/kg) or TLI (1 Cgy)) from
a HLA-identical sibling (BM: 13%; PBSC: 87%) followed by CSA.
Prior to ASCT a median of 3 lines of treatment (1–7) have been ad-
ministered over a period of 57 months (6–143).15 (48%) pts under-
went autologous SCT at a median time of 15 months (1–99) prior to
ASCT. All pts were measurable and had a median of 2 metastatic
sites (1–4) (liver:72%, bone:50%, lung:22% and brain:11%). At
transplant : 17 (55%), 10 (32%) and 4 (13%) pts had progressive
(PD), stable disease (SD) and partial response (PR) respectively.
All patients engrafted. The cumulative incidences of grade 2–4
aGVHD and cGVHD were 42% (25–59) and 62% (45–79) respec-
tively. Of note, none of the 31 pts died from TRM. Seven patients
achieved an objective response (CR 5 1; PR 5 6) at a median of
60 days (30–150) for a 24 % (9–39) OR cumulative incidence.
Eventually all pts but 3 progressed at a median of 310 days (120–
560) post transplant. Four pts are alive at median of 23 months
(21–30) post transplant for a 2-year overall survival (OS) probabil-
ity of 29% (16–47)). Results are dramatically different in regards to
disease status at time of transplant. While outcome was uniformly
poor for pts with PD (OR 5 0; 2 year OS probability: 6% (1–27)),
